PT - JOURNAL ARTICLE AU - MacDonald, Shannon E. AU - Reifferscheid, Laura AU - Paudel, Yuba Raj AU - Robinson, Joan TI - Coverage and correlates of COVID-19 vaccination among children aged 5-11 years in Alberta, Canada AID - 10.1101/2022.08.29.22279354 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.29.22279354 4099 - http://medrxiv.org/content/early/2022/08/30/2022.08.29.22279354.short 4100 - http://medrxiv.org/content/early/2022/08/30/2022.08.29.22279354.full AB - Background and Objectives In Alberta, Canada, the COVID-19 vaccination program for children aged 5-11 years opened on November 26, 2021. Our objectives were to determine the cumulative vaccine coverage, stratified by age, during the first seven months of vaccine availability, and investigate factors associated with vaccine uptake.Methods This retrospective cohort study used population-based administrative health data to assess COVID-19 vaccination coverage among children aged 5-11 years in Alberta, Canada. We determined cumulative vaccine coverage since the time of vaccine availability and used a modified Poisson regression to evaluate factors associated with vaccine uptake.Results Of 377,753 eligible children, 43.8 % (n=165,429) received one or more doses of COVID-19 vaccine during the study period (11.2% received only one dose, while 32.5 % received 2 doses). Almost 90% of initial doses were received within the first two months of vaccine availability. Of those eligible for a second dose, only 75.1% (n=122,973) received it during the study time period. We found a step-wise relationship between increasing child age and higher vaccine coverage. Other factors associated with higher vaccine coverage included living in a neighborhood with higher income, in a more densely populated area, and in certain geographic health zones. Registration in a private school was associated with lower vaccine coverage.Conclusions Messaging around COVID-19 vaccine safety and need should be tailored to child age, rather than uniform across the 5-11 year age range. Opportunities for targeted vaccination interventions should be considered.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded byAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Health Research Ethics Board of the University of Alberta gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe steward of the data used in this study is the Alberta Ministry of Health, who maintains the data for the purpose of health system administration. Thus, the authors are not at liberty to make the data publicly available.